NMN vs Nicotinamide Riboside: What the Research Compares

Both names describe neighbours on the same pathway

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are not the same molecule, but they are chemically adjacent. NR consists of nicotinamide attached to a ribose sugar. NMN is that same arrangement carrying an additional phosphate group. Neither compound is a peptide; both are small molecule derivatives of vitamin B3 studied as precursors of nicotinamide adenine dinucleotide (NAD+). A 2018 Cell Metabolism review grouped NMN and NR together as NAD+ intermediates and summarised the biology and therapeutic potential reported for each (PMID 29249689). A 2024 Nature Reviews Molecular Cell Biology article described NAD+ as a cofactor whose cellular level reflects the balance between synthesis and consumption, and reviewed the regulation of and challenges in targeting NAD+ metabolism (PMID 39026037).

The relationship between the two matters for reading any comparison. Because NR can be phosphorylated to NMN inside cells and NMN can be dephosphorylated back toward NR, experiments on one compound frequently inform interpretation of the other. The 2018 Cell Metabolism review treated NMN and NR as parts of a shared salvage route rather than as unrelated interventions (PMID 29249689). That shared destination is the reason published work rarely frames the two as rivals. Separate overviews of each compound are maintained at /learn/nmn/ and /learn/nicotinamide-riboside/.

Class, framing and regulatory status side by side

On regulatory classification in the United States, neither molecule holds approval as a drug for a disease indication. NR has been the subject of new dietary ingredient notifications submitted to the Food and Drug Administration, while the agency has stated that NMN is excluded from the statutory dietary supplement definition on the grounds that it was authorised for investigation as a new drug. Regulatory positions are revised over time, and this page is not legal advice.

Head to head evidence: what exists and what does not

There is no published randomised controlled trial within the verified literature summarised here that compared NMN against NR directly in humans using the same endpoints, the same participants and the same analytical methods. Claims that one precursor outperforms the other therefore rest on indirect comparison across studies that differ in species, model, endpoint and assay.

The closest direct comparison in this citation set is preclinical. A 2025 Science Advances study examined both nicotinamide riboside and nicotinamide mononucleotide and reported that each facilitated NAD+ synthesis via enterohepatic circulation, placing the gut and the liver on the route between an orally delivered precursor and tissue NAD+ (PMID 40117359). Because both compounds were examined in the same experimental system, that paper is the most useful anchor for anyone trying to understand whether the two behave similarly after ingestion.

Elsewhere the comparisons are narrative rather than experimental. A 2023 review in Current Nutrition Reports considered NMN and NR together and discussed their potential dietary contribution to health (PMID 37273100). A PRISMA guided systematic review published in Ageing Research Reviews collected preclinical and clinical evidence on NAD+ supplementation for anti ageing and wellness, treating the precursor literature as a single body of work rather than ranking one molecule above another (PMID 41655607).

Mechanism: where the two routes converge and where they differ

The shared destination

Both molecules feed the salvage pathway that regenerates NAD+ from nicotinamide containing building blocks. The 2018 Cell Metabolism review described NMN and NR as the two intermediates that have attracted the most attention as NAD+ boosting agents, and it summarised the enzymatic steps that link them (PMID 29249689). The 2024 Nature Reviews article emphasised that NAD+ concentration is not set by supply alone, since consuming enzymes and compartment specific regulation also shape the pool, which is one reason the review framed therapeutic targeting of this pathway as challenging (PMID 39026037).

Transport and absorption

One of the clearest mechanistic differences reported between the two involves transport. A 2019 Nature Metabolism study identified Slc12a8 as a nicotinamide mononucleotide transporter and reported its expression in the small intestine, describing a route by which NMN itself could be taken up rather than being fully degraded first (PMID 31131364). The existence and importance of a dedicated NMN transporter has remained a discussed topic in the field, and the 2025 Science Advances work added a complementary picture in which both NR and NMN contributed to NAD+ synthesis through enterohepatic circulation (PMID 40117359).

Why measurement complicates any comparison

Comparing two precursors depends on measuring the same outcome reliably. A 2023 paper in Nutrients set out to define NAD(P)(H) catabolism, describing the degradation routes and breakdown products that influence how dinucleotide pools are interpreted in biological samples (PMID 37447389). Differences in sample handling and analytical approach across laboratories make cross study comparison between NMN experiments and NR experiments less straightforward than a simple table of numbers would suggest.

What the separate evidence bases have measured

Whole body and clinical endpoints

The systematic review in Ageing Research Reviews applied PRISMA methodology to preclinical and clinical evidence on NAD+ supplementation in the context of ageing and wellness, which places human trials of these precursors alongside the much larger animal literature (PMID 41655607). The 2023 Current Nutrition Reports review approached the same compounds from a nutrition standpoint, discussing dietary sources and the health relevance proposed for NMN and NR (PMID 37273100).

Tissue specific preclinical models

Much of the mechanistic work concerns NAD+ metabolism itself rather than a head to head test of precursors. A 2024 article in Adipocyte reviewed the function of NAD metabolism in white adipose tissue using lessons drawn from mouse models (PMID 38316756). A 2025 paper in Clinical and Translational Medicine reported that altered nicotinamide adenine dinucleotide metabolism drives cartilage degeneration and osteoarthritis (PMID 41194652). These are statements about the pathway rather than endorsements of either precursor.

Adjacent mitochondrial quality control literature

Readers comparing NMN and NR often encounter mitophagy research in the same discussions. A 2022 Autophagy review described the multifaceted regulation of mitophagy by endogenous metabolites (PMID 34583624), and a 2025 Autophagy study reported that urolithin A modulated inter organellar communication via calcium dependent mitophagy in a healthy ageing context (PMID 40944367). Urolithin A is a different compound from either NAD+ precursor, and those findings should not be transferred to NMN or NR.

Safety Signals and Adverse Events: What Studies Report

The most discussed mechanistic caution specific to NMN concerns the sterile alpha and TIR motif containing protein 1 pathway. A 2021 Neuron study reported that SARM1 functions as a metabolic sensor activated by an increased NMN to NAD+ ratio, and that this activation triggered axon degeneration in the experimental systems examined (PMID 33657413). That finding describes a ratio dependent mechanism in laboratory models and was not a report of clinical adverse events in people.

At the pathway level, the 2024 Nature Reviews Molecular Cell Biology article set out the difficulties of manipulating NAD+ metabolism therapeutically, including the regulation that constrains how far a supplied precursor changes the pool (PMID 39026037). The PRISMA guided systematic review assembled the available preclinical and clinical evidence on NAD+ supplementation, which is the appropriate place to look for how tolerability has been assessed across human studies to date (PMID 41655607).

Open questions the literature has not settled

• Whether NMN and NR produce comparable tissue NAD+ changes when given under identical conditions, since the available direct comparison was preclinical (PMID 40117359).
• How much of an orally supplied precursor reaches tissues intact versus being processed in the gut and liver (PMID 40117359).
• The physiological weight of dedicated transport, following the identification of Slc12a8 as an NMN transporter (PMID 31131364).
• Whether precursor ratios matter as much as absolute NAD+ levels, given the ratio sensitive SARM1 mechanism reported in 2021 (PMID 33657413).
• How consistently NAD(P)(H) pools and their catabolites are measured between laboratories (PMID 37447389).

Reading a comparison that has no declared winner

When two interventions share a pathway and have never been tested against each other in a randomised human trial, the honest description is that the evidence bases run in parallel. The reviews that cover both molecules describe them as related NAD+ intermediates rather than competitors (PMID 29249689, PMID 37273100). This page is for educational purposes only and is not medical advice; consult a licensed physician before making any decision related to supplements, medications or health conditions.

References

• NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR (Cell Metabolism, 2018)
• Regulation of and challenges in targeting NAD(+) metabolism (Nature Reviews Molecular Cell Biology, 2024)
• NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (Current Nutrition Reports, 2023)
• Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD(+) synthesis via enterohepatic circulation (Science Advances, 2025)
• Defining NAD(P)(H) Catabolism (Nutrients, 2023)
• NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence (Ageing Research Reviews, 2026)
• SARM1 is a metabolic sensor activated by an increased NMN/NAD(+) ratio to trigger axon degeneration (Neuron, 2021)
• Slc12a8 is a nicotinamide mononucleotide transporter (Nature Metabolism, 2019)
• Function of NAD metabolism in white adipose tissue: lessons from mouse models (Adipocyte, 2024)
• Altered nicotinamide adenine dinucleotide metabolism drives cartilage degeneration and osteoarthritis (Clinical and Translational Medicine, 2025)
• The multifaceted regulation of mitophagy by endogenous metabolites (Autophagy, 2022)
• Urolithin A modulates inter-organellar communication via calcium-dependent mitophagy to promote healthy ageing (Autophagy, 2025)